PLA1/A2 polymorphism of the platelet glycoprotein receptor IIb/IIIa in young patients with cryptogenic TIA or ischemic stroke

Goor, M; García, Encarna Gómez; Brouwers, Geert-Jan; Leebeek, Frank W.G.; Koudstaal, Peter J.; Dippel, Diederik W.J.

doi:10.1016/s0049-3848(02)00356-0

Cited by 22 publications

(10 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…57 Current data are conflicting as to whether this conformational change increases or decreases binding to immobilized fibrinogen, thereby affecting fibrin clot retraction. 58 It is plausible that the GPIIIa rs5918 C allele might play a role in stroke etiology, given that this allele has been linked to an increased risk of stroke. 59 Our study has several limitations.…”

Section: Discussionmentioning

confidence: 99%

Impact of COX-2 rs5275 and rs20417 and GPIIIa rs5918 Polymorphisms on 90-Day Ischemic Stroke Functional Outcome: A Novel Finding

Maguire¹,

Thakkinstian²,

Levi³

et al. 2011

Journal of Stroke and Cerebrovascular Diseases

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Impact of COX-2 rs5275 and rs20417 and GPIIIa rs5918 Polymorphisms on 90-Day Ischemic Stroke Functional Outcome: A Novel Finding

Maguire¹,

Thakkinstian²,

Levi³

et al. 2011

Journal of Stroke and Cerebrovascular Diseases

View full text Add to dashboard Cite

“…Even though several positive studies exist, there is also a number of minor controversies concerning the functional role of rs5918 in different populations, which do not support any association between rs5918 polymorphism and ischemic stroke [9,28,32,44,45,[60][61][62][63]. In an initially performed meta-analysis, which included 26 studies with five referring to rs5918 polymorphism, a dominant genetic model revealed no linkage with ischemic stroke [49].…”

Section: Gpiib/iiia -Itga2b and Itgb3 Genesmentioning

confidence: 99%

Common Genetic Variants in Platelet Surface Receptors and its Association with Ischemic Stroke

et al. 2016

View full text Add to dashboard Cite

Ischemic stroke has been named one of the leading causes of death worldwide. Whereas numerous biological mechanisms and molecules were found to be associated with stroke, platelets are particularly contributive to its pathogenesis. Recent data indicate considerable variability in platelet phenotype which accounts for differences in platelet surface receptor function, count and reactivity. These features collectively influence both the events leading to a disease and effectiveness of antiplatelet therapies. Consequently, genetic variants predisposing to cerebrovascular diseases can be sequenced using a wide array of techniques and become a useful tool in clinical setting. In this review, we provide an outline of common platelet polymorphisms that impose risk on ischemic stroke development and should be evaluated as targets to improve treatment. As study results are often inconsistent, partly due to differences in demographic characteristics between study populations and the fact that the functional impact of these variants has been relatively small, we conclude that both rare, low-frequency and common variants might account for genetic contribution on abnormal platelet response to antiplatelet drugs.

show abstract

“…In contrast, genetic analyses from the Physicians’ Health study did not demonstrate relevant differences of allele distribution in 374 patients with prior myocardial infarction compared with 704 matched controls [13]. Although initial data provided some evidence that the HPA‐1 polymorphism might influence the re‐stenosis rate after percutaneous coronary intervention (PCI) [14,15], subsequent clinical trials could not confirm a clear prognostic relevance of this polymorphism regarding reperfusion success and clinical outcome in patients with symptomatic coronary artery disease [16,17] or cerebrovascular disease [18]. Further studies suggested that the HPA‐1 polymorphism may play a crucial role for premature ischemic events, thus characterizing this genetic variant as a risk factor for early atherothrombosis instead of atherosclerosis [19].…”

Section: Platelet Surface Receptors: Polymorphic Variants and Their Rmentioning

confidence: 99%

Platelet pharmacogenomics

Zuern

Schwab

Gawaz

et al. 2010

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

Summary. Platelet responsiveness to conventional antiplatelet therapy underlies a high interindividual variability influenced by various factors. For instance, antiplatelet therapy does not curtail the expected effects in a relevant number of patients as demonstrated by the occurrence of repeated cardiovascular events including stent thrombosis and/or by inadequate platelet inhibition measured by in vitro platelet function assays. Besides non-genetic factors such as age, gender, liver and renal function and co-medication, considerable variation of antiplatelet drug responsiveness can be attributed to genetic factors including polymorphisms and genetic variants of platelet surface proteins and drug metabolizing enzymes. Nowadays, platelet pharmacogenomics has started a new field with the goal to link genetic information of various drug targets to interindividual variability of drug response. Evolving data from large cohort studies suggest a promising role for pharmacogenomics in the context of antiplatelet therapy. Additionally, with the revolution of low cost and high-throughput genotyping techniques, genetic testing has become affordable for clinical application and individualization of therapy. However, a key issue to define the future role of pharmacogenomics will rely on the benefit and the timeliness of implementing the genetic information into therapeutic decision. Hence, it warrants further investigations to document the prognostic effects of therapeutic alterations in distinct genotypes. Concerning the safety profile of emerging antiplatelet and antithrombotic drugs in certain risk groups it would be fatal to individualize treatment barely on behalf of an atherothrombotic genotype. In contrast, individual risk assessment combining non-genetic information and pharmacogenetic analysis represents a reasonable concept. Here, we provide a review on current data describing the role of pharmacogenomics in the field of antiplatelet drug treatment in cardiovascular patients with future directions.

show abstract

PLA1/A2 polymorphism of the platelet glycoprotein receptor IIb/IIIa in young patients with cryptogenic TIA or ischemic stroke

Cited by 22 publications

References 22 publications

Impact of COX-2 rs5275 and rs20417 and GPIIIa rs5918 Polymorphisms on 90-Day Ischemic Stroke Functional Outcome: A Novel Finding

Impact of COX-2 rs5275 and rs20417 and GPIIIa rs5918 Polymorphisms on 90-Day Ischemic Stroke Functional Outcome: A Novel Finding

Common Genetic Variants in Platelet Surface Receptors and its Association with Ischemic Stroke

Platelet pharmacogenomics

Contact Info

Product

Resources

About